In November, there was a sizeable reduction in the number of short positions held in Erasca, Inc. (NASDAQ: ERAS). As of November 15th, there were 15,970,000 shares available for a short sale; as of November 30th, there were only 14,460,000 shares available for a short sale. This is a drop of 9.5% from the previous value. Approximately 21.8% of the total number of shares that are issued and outstanding in the company are sold short. The current short-interest ratio is 22.0 days; this number is derived from the stock’s average trading volume of 658,300 shares. This number indicates there is currently 22.0 days’ worth of short positions.
Recent months have seen several institutional investors, including hedge funds and other types of investment funds, adjust the overall number of shares held in their portfolios. During the third quarter of this year, there was a 16.9% increase in value associated with the interests held by Jane Street Group LLC in Itasca. In the most recent fiscal period, Jane Street Group LLC made an additional purchase of 1,958 shares. This brings the total number of shares that the company owns in the enterprise to 13,557, with a value of $106,000. During the first three months of 2018, ProShare Advisors LLC made a 13.2% purchase of additional Erasca shares, bringing its total number of these shares to a total of 1.4%. The value of ProShare Advisors LLC’s holdings has increased to $211,000 due to the addition of 2,858 new shares of the company’s stock that were purchased since the beginning of this quarter. During the second quarter, Allspring Global Investments Holdings LLC brought the total amount of Erasca stock it owned to 9.0 percent higher than before. Allspring Global Investments Holdings LLC now owns 35,775 shares of the company’s stock, currently valued at $199,000. This is a result of the previous quarter’s purchase of the same number of shares, which brought the total number of shares owned by this entity to the same level. By purchasing additional stock in the previous quarter, the company had already increased its total number of shares by 2,965 since the beginning of the fiscal year. The amount of Erasca stock that Ameritas Investment Partners Inc. owned increased by 212.7% during the first three months of the year, resulting in a company gain of 212.7%. After purchasing an additional 3,372 shares over the previous three months, Ameritas Investment Partners Inc. now owns 4,957 shares, which are $43,000. This brings the total number of shares directly owned by the company to 4,957. During the first quarter, the Swiss National Bank increased the amount of Erasca stock owned by 7.5%, making this the last and most important point. During the most recent quarter, the Swiss National Bank purchased an additional 4,000 shares of the company’s stock, which increased the total number of shares owned by the institution to 57,400. The stock holdings of the bank currently have a market value of $494,000edge funds and other types of investment funds adjust the overall number of shares held in their portfolios. During the third quarter of this year, there was a 16.9% increase in value associated with the interests held by Jane Street Group LLC in Itasca. In the most recent fiscal period, Jane Street Group LLC made an additional purchase of 1,958 shares. This brings the total number of shares that the company owns in the enterprise to 13,557, with a value of $106,000. During the first three months of 2018, ProShare Advisors LLC made a 13.2% purchase of additional Erasca shares, bringing its total number of these shares to a total of 1.4%. The value of ProShare Advisors LLC’s holdings has increased to $211,000 due to the addition of 2,858 new shares of the company’s stock that were purchased since the beginning of this quarter. During the second quarter, Allspring Global Investments Holdings LLC brought the total amount of Erasca stock it owned to 9.0 percent higher than before. Allspring Global Investments Holdings LLC now owns 35,775 shares of the company’s stock, currently valued at $199,000. This is a result of the previous quarter’s purchase of the same number of shares, which brought the total number of shares owned by this entity to the same level. By purchasing additional stock in the previous quarter, the company had already increased its total number of shares by 2,965 since the beginning of the fiscal year. The amount of Erasca stock that Ameritas Investment Partners Inc. owned increased by 212.7% during the first three months of the year, resulting in a company gain of 212.7%. After purchasing an additional 3,372 shares over the previous three months, Ameritas Investment Partners Inc. now owns 4,957 shares, which are $43,000. This brings the total number of shares directly owned by the company to 4,957. During the first quarter, the Swiss National Bank increased the amount of Erasca stock owned by 7.5%, making this the last and most important point. During the most recent quarter, the Swiss National Bank purchased an additional 4,000 shares of the company’s stock, which increased the total number of shares owned by the institution to 57,400. The stock holdings of the bank currently have a market value of $494,000. Currently, 63.000% of the company’s outstanding shares are owned by institutional investors and hedge funds.
Alexander W. Casdin, the director of Eurasia, purchased 20,000 shares of the company’s stock on December 15th. Another recent piece of news is as follows: The cost of purchasing all of the shares of stock came to a total of $97,400.00, which works out to an average of $4.87 for each share. After the completion of the transaction, the director now owns a total of 443,974 shares of the company’s stock, which have a value of approximately $2,162,153.38. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available. According to information from other sources, on December 15th, Director Alexander W. Casdin bought 20,000 Erasca stock. Other news sources reported this transaction. Because the price per share reached an average of $4.87, the overall expense of purchasing the stock totaled $97,400.00. After the completion of the transaction, the director now owns a total of 443,974 shares of the company’s stock, which have a value of approximately $2,162,153.38. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available. In addition, on December 14th, Jonathan E. Lim, the CEO of Erasca, purchased 40,000 shares of the company’s stock for his investment portfolio. The stock was acquired for a total price of $199,600.00, which works out to an average price of $4.99 per share. After the transaction’s completion, the company’s CEO now directly owns 20,196,222 shares of the company, which have a combined value of approximately $100,779,147.78. You should look in this location if you are looking for the disclosure that pertains to this transaction. At the moment, company insiders hold ownership of 37.50% of the company’s total stock.
At the opening of trading on Monday, the price of a share of ERAS stock was $4.55. Over the previous 52 weeks, the cost of an Erasca pill could have ranged anywhere from $4.46 to $16.00. The simple moving average of the company’s stock price over the past 50 days is $7.10, and its average stock price over the last 200 days is $7.30. A price-to-earnings ratio of -3.92 and a beta value of 0.99 are both associated with the business. The company’s current value, as measured by its capitalization on the market, is $556.75 million.
Itasca (NASDAQ: ERAS) made its most recent earnings report available to the public on November 9th. This report was made public approximately one month ago. The company generated $0.29 in profits per share during the quarter, which is $0.02 higher than the analysts’ consensus estimate, which was $0.31. This sentence is slightly different from the one presented in the video in terms of the language being used.
Erasca, Inc. is a biopharmaceutical company developing its product and is currently in the clinical stage. Patients suffering from cancers fueled by the RAS/MAPK pathway are the primary target audience for the company’s efforts to find, develop, and market new treatments for the disease. Oral ERK1/2 inhibitor ERAS-007 is currently in the research and development stages for treating non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia. In addition, the oral SHP2 inhibitor ERAS-601 is currently under development for patients with advanced or metastatic solid cancers as part of the ERAS-601 clinical trial. Both of these potential candidates are regarded as among the most promising products the company offers.
Discussion about this post